• Prescribing Information
  • Medication Guide
  • Patient Site
  • Savings & Support

    Access Resources

    Enroll your patients to help them with access resources and support

    $0 Copay Savings Card
    The Copay Savings Card may reduce out-of-pocket costs for eligible, commercially insured patients prescribed CIBINQO. With the Copay Savings Card,* eligible commercially insured patients:
    • May pay as little as $0 out-of-pocket  
    • Receive up to a maximum benefit of $15,000 per calendar year
    ​​​​​​​​​​​​​​ Download Copay Savings Card.

    Interim Care Rx
    If a delay or coverage denial occurs during the prior authorization or appeals process, eligible, commercially insured patients enrolled in Pfizer Dermatology Patient Access
    TM may receive CIBINQO for up to 2 years at no cost shipped to them through Interim Care Rx

    Live support
    Enroll your patients in Pfizer Dermatology Patient Access
    TM for coverage assistance, specialty pharmacy coordination, financial assistance resources, and access to a Patient Support Representative

       *Eligibility required. No membership fees. The maximum benefit per patient is $15,000 per calendar year. Only for use with commercial insurance. If you are enrolled in a state or federally funded prescription insurance program, you may not use the copay card. Terms and conditions apply. 

        †The free product for this program is for certain commercially insured patients only. Not available to residents in the states of MA, MI, MN, MO, OH, or RI. See terms and conditions.

        ‡Some offerings are provided through third-party organizations that operate independently and are not controlled by Pfizer. Availability of offerings and eligibility requirements are determined solely by these organizations.

    There are 4 ways to enroll your patients for savings and support


    EHR: Electronically complete and submit the enrollment form§

    e-Prescribe directly to Sonexus Health Pharmacy Services|| 
    NCPDP: 5910206; 
    NPI: 1447680210

    HCP Portal: Log in or register at 
    PfizerDermatologyHCPPortal.com

    Fax a completed and signed enrollment form to 
    1-877-548-1734

    To learn more, call 1-844-496-8707, Monday-Friday, 8:00 AM to 8:00 PM ET
    ​​​​​​​

       §A link to enroll patients appears in the EHR during the e-prescribing process. How you are directed to the form is controlled by, and varies based on, your EHR channel partner.

       ||If you choose to ePrescribe directly to Sonexus Health Pharmacy Services, you are certifying that you have received patient consent for Sonexus Health Pharmacy Services and Pfizer Dermatology Patient AccessTM to contact your patient and provide them services. Sonexus Health Pharmacy Services is categorized as a mail-order pharmacy in EMR/EHR systems and is located at 2730 S. Edmonds Lane, Suite 400, Lewisville, TX 75067.

    Access resources​​​​​​​

    Patient Enrollment Form

    Complete, print, and fax to enroll patients in the Pfizer Dermatology Patient AccessTM program.

    Download the Form​​​​​​​

    ** This is an optional area where footnotes can live.

    HCP Portal Enrollment Form

    Complete, print, and fax to register to enroll patients in Pfizer Dermatology Patient AccessTM via the HCP Portal.

    Download the Form​​​​​​​

    ** This is an optional area where footnotes can live.

    Combined HCP and Patient Pfizer Patient Assistance Program Enrollment Form

     
    Complete, print, and mail or fax to help patients apply for free medication.
     

    Download the Form

    ** This is an optional area where footnotes can live.

    Sample Letter of Medical Necessity
    ​​​​​​​ ​​​​

    Download the Form

    Examples when requesting coverage from patients’ insurance providers.
    ​​​​​​​

    ** This is an optional area where footnotes can live.

    PFIZER PATIENT ASSISTANCE PROGRAM ELIGIBILITY CRITERIA
    The Pfizer Patient Assistance Program is not health insurance and is available for eligible uninsured/underinsured patients only. Offer is only available to patients who meet financial and other criteria. This offer does not require, nor will it be made contingent on, purchase requirements of any kind. No claim for reimbursement or credit for any costs associated with the medicine(s) may be submitted to any prescription insurance provider or payer, including Medicare Part D plans. Pfizer reserves the right to amend, rescind, or discontinue this program at any time without notification. Offer good only in the U.S. and Puerto Rico. Patient must be a resident of the U.S. or Puerto Rico. Prescription must be provided by a healthcare provider licensed in the U.S. or Puerto Rico. Patient must be treated in the outpatient setting of care. Additional eligibility criteria may apply. Contact Pfizer Dermatology Patient Access for details.

    Copay Savings Card

    Get your eligible, commercially insured patients started

    Download Copay Savings Card

    ** This is an optional area where footnotes can live.

    Start Guide

    Ready to get a patient started?

    Download the Start Guide

    ** This is an optional area where footnotes can live.

    Request an eRep​​​​​​​​​​​​​​​​​​​​​

    Connect with an eRep to learn more about CIBINQO

    Request

    ** This is an optional area where footnotes can live.

     
    Next page: Downloadable Copay Savings Card
     

    CIBINQO (abrocitinib) is indicated for the treatment of adults with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.
    ​​​​​​​

    INDICATION

    Limitations of Use: CIBINQO is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants.

    WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS, AND THROMBOSIS

    SERIOUS INFECTIONS
    Patients treated with CIBINQO may be at increased risk for developing serious infections that may lead to hospitalization or death. The most frequent serious infections reported with CIBINQO were herpes simplex, herpes zoster, and pneumonia.


    If a serious or opportunistic infection develops, discontinue CIBINQO and control the infection.

    Reported infections from Janus kinase (JAK) inhibitors used to treat inflammatory conditions: 
    • Active tuberculosis, which may present with pulmonary or extrapulmonary disease. Test for latent TB before and during therapy; treat latent TB prior to use. Monitor all patients for active TB during treatment, even patients with initial negative, latent TB test.
    • Invasive fungal infections, including cryptococcosis and pneumocystosis. Patients with invasive fungal infections may present with disseminated, rather than localized, disease. 
    • Bacterial, viral (including herpes zoster), and other infections due to opportunistic pathogens.
    ​​​​​​​Avoid use of CIBINQO in patients with an active, serious infection, including localized infections. The risks and benefits of treatment with CIBINQO should be carefully considered prior to initiating therapy in patients with chronic or recurrent infections or those who have resided or traveled in areas of endemic tuberculosis or endemic mycoses.

    Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with CIBINQO, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.

    Consider yearly screening for patients in highly endemic areas for TB. CIBINQO is not recommended for use in patients with active TB. For patients with a new diagnosis of latent TB or prior untreated latent TB, or for patients with a negative test for latent TB but who are at high risk for TB infection, start preventive therapy for latent TB prior to initiation of CIBINQO. 

    Viral reactivation, including herpes virus reactivation (eg, herpes zoster, herpes simplex), was reported in clinical studies with CIBINQO. If a patient develops herpes zoster, consider interrupting CIBINQO until the episode resolves. Hepatitis B virus reactivation has been reported in patients receiving JAK inhibitors. Perform viral hepatitis screening and monitoring for reactivation in accordance with clinical guidelines before starting therapy and during therapy with CIBINQO. CIBINQO is not recommended for use in patients with active hepatitis B or hepatitis C.

    MORTALITY
    In a large, randomized postmarketing safety study in rheumatoid arthritis (RA) patients 50 years of age and older with at least one cardiovascular risk factor comparing another JAK inhibitor to TNF blocker treatment, a higher rate of all-cause mortality (including sudden cardiovascular death) was observed with the JAK inhibitor. CIBINQO is not approved for use in RA patients.


    MALIGNANCIES
    Malignancies, including non-melanoma skin cancer (NMSC), were reported in patients treated with CIBINQO. Lymphoma and other malignancies have been observed in patients receiving JAK inhibitors used to treat inflammatory conditions.
    Perform periodic skin examination for patients who are at increased risk for skin cancer. Exposure to sunlight and UV light should be limited by wearing protective clothing and using broad-spectrum sunscreen.

    In a large, randomized postmarketing safety study of another JAK inhibitor in RA patients, a higher rate of malignancies (excluding non-melanoma skin cancer [NMSC]) was observed in patients treated with the JAK inhibitor compared to those treated with TNF blockers. CIBINQO is not approved for use in RA patients. A higher rate of lymphomas was observed in patients treated with the JAK inhibitor compared to those treated with TNF blockers. A higher rate of lung cancers was observed in current or past smokers treated with the JAK inhibitor compared to those treated with TNF blockers. Patients who are current or past smokers are at additional increased risk.


    Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with CIBINQO, particularly in patients with a known malignancy (other than a successfully treated NMSC), patients who develop a malignancy when on treatment, and patients who are current or past smokers.

    MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE)  
    Major adverse cardiovascular events were reported in patients treated with CIBINQO. In RA patients 50 years of age and older with at least one cardiovascular risk factor treated with another JAK inhibitor, a higher rate of major adverse cardiovascular events (MACE) (defined as cardiovascular death, myocardial infarction, and stroke), was observed when compared with TNF blockers.
    CIBINQO is not approved for use in RA patients. Patients who are current or past smokers are at additional increased risk. Discontinue CIBINQO in patients that have experienced a myocardial infarction or stroke.


    Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with CIBINQO, particularly in patients who are current or past smokers and patients with other cardiovascular risk factors. Patients should be informed about the symptoms of serious cardiovascular events and the steps to take if they occur. 

    THROMBOSIS
    Deep vein thrombosis (DVT) and pulmonary embolism (PE) have been reported in patients treated with CIBINQO. Thrombosis, including PE, DVT, and arterial thrombosis have been reported in patients receiving JAK inhibitors used to treat inflammatory conditions. Many of these adverse reactions were serious and some resulted in death. In RA patients 50 years of age and older with at least one cardiovascular risk factor treated with another JAK inhibitor, a higher rate of overall thrombosis, DVT, and PE were observed when compared with TNF blockers.
    CIBINQO is not approved for use in RA patients.

    Avoid CIBINQO in patients that may be at increased risk of thrombosis. If symptoms of thrombosis occur, discontinue CIBINQO and treat patients appropriately.


    CONTRAINDICATION
    CIBINQO is contraindicated in patients taking antiplatelet therapies, except for low-dose aspirin (≤81 mg daily), during the first 3 months of treatment.


    LABORATORY ABNORMALITIES
    Hematologic Abnormalities: Treatment with CIBINQO was associated with an increased incidence of thrombocytopenia and lymphopenia. Prior to CIBINQO initiation, perform a complete blood count (CBC). CBC evaluations are recommended at 4 weeks after initiation and 4 weeks after dose increase of CIBINQO. Discontinuation of CIBINQO therapy is required for certain laboratory abnormalities. 

    Lipid Elevations: Dose-dependent increase in blood lipid parameters were reported in patients treated with CIBINQO. Lipid parameters should be assessed approximately 4 weeks following initiation of CIBINQO therapy, and thereafter patients should be managed according to clinical guidelines for hyperlipidemia. The effect of these lipid parameter elevations on cardiovascular morbidity and mortality has not been determined. 


    IMMUNIZATIONS
    Prior to initiating CIBINQO, complete all age-appropriate vaccinations as recommended by current immunization guidelines, including prophylactic herpes zoster vaccinations. Avoid vaccination with live vaccines immediately prior to, during, and immediately after CIBINQO therapy.


    RENAL IMPAIRMENT
    Avoid use in patients with severe renal impairment or end stage renal disease, including those on renal replacement therapy.

    HEPATIC IMPAIRMENT
    Avoid use in patients with severe hepatic impairment.

    ADVERSE REACTIONS
    Most common adverse reactions (≥1%) in subjects receiving 100 mg and 200 mg include: nasopharyngitis, nausea, headache, herpes simplex, increased blood creatinine phosphokinase, dizziness, urinary tract infection, fatigue, acne, vomiting, oropharyngeal pain, influenza, gastroenteritis. 

    Most common adverse reactions (≥1%) in subjects receiving either 100 mg or 200 mg also include: impetigo, hypertension, contact dermatitis, upper abdominal pain, abdominal discomfort, herpes zoster, and thrombocytopenia.

    Inform patients that retinal detachment has been reported in CIBINQO clinical trials. Advise patients to immediately inform their healthcare provider if they develop any sudden changes in vision.

    DRUG INTERACTIONS
    Monitor appropriately or dose titrate P-gp substrate where small concentration changes may lead to serious or life-threatening toxicities when coadministered with CIBINQO. See Prescribing Information for clinically relevant drug interactions.

    USE IN PREGNANCY
    Available data from pregnancies reported in clinical trials with CIBINQO are not sufficient to establish a drug-associated risk for major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Advise females of reproductive potential that CIBINQO may impair fertility.

    There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to CIBINQO during pregnancy. Pregnant women exposed to CIBINQO and health care providers are encouraged to call 1-877-311-3770. 

    LACTATION
    Advise women not to breastfeed during treatment with CIBINQO and for one day after the last dose.


    Please see full Prescribing Information, including BOXED WARNING, and Medication Guide. 

    CIBINQO is indicated for the treatment of adults with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.

    Limitations of Use: CIBINQO is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants.